2 results
Approved WMORecruiting
To investigate how safe the new medicine pralsetinib is when it is administered to patients with non-resectable advanced solid tumor cancers including non-small cell lung cancer (NSCLC) and Thyroid cancers.
Approved WMORecruiting
This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary activity, and biomarkers of GDC-6036 as a single agent (Arm A) and in combination with other anti-cancer…